10-K: Quince Therapeutics Reports Full Year 2023 Results, Prioritizes Rare Disease Pipeline

Quince Therapeutics, Inc. released its 10-K filing for fiscal year 2023, highlighting its strategic shift towards rare disease therapeutics and the advancement of its lead asset, EryDex.

Summary

• Quince Therapeutics, Inc. has filed its annual report for the fiscal year ended December 31, 2023, detailing a strategic shift towards rare disease therapeutics.
• The company completed the acquisition of EryDel in October 2023, bringing in a proprietary AIDE technology platform and a Phase 3 lead asset, EryDex, for the treatment of Ataxia-Telangiectasia (A-T).
• Quince is prioritizing the Phase 3 NEAT clinical trial for EryDex, with enrollment expected to begin in the second quarter of 2024 and top-line results anticipated in the second half of 2025.
• The company believes it is well-capitalized into 2026, with $75.1 million in cash, cash equivalents, and investments as of December 31, 2023.
• Quince sold its legacy small molecule protease inhibitor portfolio in January 2023 and terminated a license agreement for its bone-targeting drug platform.
• The company incurred a net loss of $31.4 million for the year ended December 31, 2023, and has an accumulated deficit of $319.6 million.
• The AIDE technology platform uses a patient's own red blood cells to deliver drugs, potentially improving tolerability, tissue distribution, and reducing immunogenicity.
• EryDex is designed to encapsulate dexamethasone sodium phosphate (DSP) in red blood cells to treat A-T, a rare neurodegenerative disease with no approved treatments.
• The global market for A-T treatments is estimated to be a $1+ billion peak commercial opportunity.
• The Phase 3 NEAT trial will enroll approximately 86 patients aged 6-9 years and 20 patients aged 10 years or older, and is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the strategic shift and acquisition of EryDel are positive, the company's financial losses, reliance on a single lead asset, and the risks associated with clinical development temper the overall sentiment. The company's cash runway is a positive, but the need for future capital raises is a concern.

Positives

• The acquisition of EryDel provides a promising late-stage asset and a novel drug delivery platform.
• The company has a clear strategic focus on rare diseases with a significant market opportunity.
• The Phase 3 NEAT trial is being conducted under an SPA agreement with the FDA, potentially streamlining the regulatory approval process.
• The company believes it has sufficient capital to fund operations into 2026.
• The AIDE technology platform has the potential to improve drug delivery and reduce side effects.

Negatives

• The company incurred a net loss of $31.4 million for the year ended December 31, 2023, and has an accumulated deficit of $319.6 million.
• The previous Phase 3 ATTeST trial for EryDex did not meet its primary endpoint.
• The company has no approved products and has never generated revenue from sales.
• The company is dependent on the success of EryDex, which is still in clinical development.
• The company may be required to make milestone payments to EryDel shareholders or pursuant to the EIB Facility, which could adversely affect the overall profitability of EryDex, if approved.

Risks

• The company may experience difficulties integrating Quince and EryDel's operations.
• The Phase 3 NEAT clinical trial may be delayed, may not be successful, and may not result in NDA approval.
• The company will require additional capital to fund the development of EryDex.
• Clinical trials of drug candidates may not uncover all possible adverse events.
• The company may not be able to successfully demonstrate a favorable differentiation between EryDex and currently available corticosteroids.
• The potential rare disease target patient populations of EryDex are small, which may make it difficult to complete clinical trials or commercialize the drug candidate.
• The company relies on third parties for clinical trials and manufacturing, which may not perform satisfactorily.
• The company may not be able to obtain and maintain sufficient intellectual property protection for its drug candidates.
• The company may face competition from other companies developing treatments for A-T.

Future Outlook

The company intends to focus its development expertise and financial resources toward the advancement of its proprietary AIDE technology platform and Phase 3 lead asset, EryDex. The company plans to complete start-up activities for the Phase 3 NEAT clinical trial by the end of the second quarter of 2024, enroll the first patient in the second quarter of 2024, report top-line results in the second half of 2025, and prepare for a U.S. NDA submission in 2026, provided positive study results are obtained. The company also plans to pursue potential strategic partnerships to out-license ex-U.S. regional territories.

Management Comments

• The company believes it is well-capitalized into 2026 and intends to focus its development expertise and financial resources toward the advancement of its proprietary AIDE technology platform and Phase 3 lead asset, EryDex.
• The company benefits from a strong senior leadership team who possess a wide range of biotech expertise that encompasses all stages of drug development, regulatory submission and approval, and commercialization.

Industry Context

The company's strategic shift towards rare disease therapeutics aligns with a growing focus in the pharmaceutical industry on addressing unmet medical needs in smaller patient populations. The acquisition of EryDel and the prioritization of EryDex for A-T positions Quince in a competitive space with potential for significant market opportunities.

Comparison to Industry Standards

• The company's focus on a rare disease with no approved treatments is similar to other biotech companies targeting niche markets.
• The use of a proprietary drug delivery platform like AIDE is a common strategy to differentiate products and improve efficacy and safety profiles.
• The company's cash runway into 2026 is comparable to other clinical-stage biotech companies, but the need for additional funding is a common risk.
• The company's reliance on third-party manufacturers and CROs is standard practice in the biotech industry.
• The company's approach of using the 505(b)(2) regulatory pathway is a common strategy for developing new formulations of existing drugs.

Related Party Transactions

• David Lamond, Chairperson of the Board of Quince Therapeutics, Inc. was a director and an equity holder in Novosteo which Quince acquired on May 19, 2022.
• Dirk Thye, M.D., Chief Executive Officer, is an investor in Morphimmune Inc. and Philip Low, Ph.D, a former Board member of Quince Therapeutics, Inc., is a co-founder and Board member of Morphimmune Inc. During the year ended December 31, 2023, the Company sold certain lab equipment to Morphimmune Inc. for $ 80,000 as well as signed a sublease with Morphimmune as the sublessee with total payments of approximately $ 57,000 for the lease term of March 17, 2023 through December 31, 2023.

Stakeholder Impact

• Shareholders face the risk of dilution from future capital raises and potential losses if the company's drug candidates fail.
• Employees may experience job insecurity due to the company's cost reduction programs and strategic shifts.
• Patients with A-T stand to benefit from the potential development of EryDex, which could be the first approved treatment for the disease.
• Suppliers and creditors may face risks related to the company's financial performance and ability to meet its obligations.

Next Steps

• Complete start-up activities for the Phase 3 NEAT clinical trial by the end of the second quarter of 2024.
• Enroll the first patient in the Phase 3 NEAT clinical trial in the second quarter of 2024.
• Report Phase 3 NEAT clinical trial top-line results in the second half of 2025.
• Prepare for a U.S. NDA submission in 2026, provided positive NEAT study results are obtained.
• Pursue potential strategic partnerships to out-license ex-U.S. regional territories.

Key Dates

Keywords

EryDex, Ataxia-Telangiectasia, AIDE technology, rare diseases, clinical trial, biotechnology, drug delivery, red blood cells, dexamethasone sodium phosphate, neurodegenerative disease